Skip to Main content Skip to Navigation
New interface
Journal articles

Is TWEAK a Biomarker for Autoimmune/Chronic Inflammatory Diseases?

Abstract : The TWEAK/Fn14 pathway is now well-known for its involvement in the modulation of inflammation in various human autoimmune/chronic inflammatory diseases (AICID) including lupus, rheumatoid arthritis, and multiple sclerosis. A panel of data is now available concerning TWEAK expression in tissues or biological fluids of patients suffering from AICID, suggesting that it could be a promising biological marker in these diseases. Evidences from several teams support the hypothesis that blocking TWEAK/Fn14 pathway is an attractive new therapeutic lead in such diseases and clinical trials with anti-TWEAK-blocking antibodies are in progress. In this mini-review we discuss the potential use of TWEAK quantification in AICD management in routine practice and highlight the challenge of standardizing data collection to better estimate the clinical utility of such a biological parameter.
Document type :
Journal articles
Complete list of metadata

Cited literature [32 references]  Display  Hide  Download
Contributor : Denis Becquet Connect in order to contact the contributor
Submitted on : Wednesday, April 18, 2018 - 10:25:36 AM
Last modification on : Tuesday, October 19, 2021 - 10:59:49 PM


Publication funded by an institution


Distributed under a Creative Commons Attribution 4.0 International License




Daniel Bertin, Delphine Stephan, Michel Khrestchatisky, Sophie Desplat-Jégo. Is TWEAK a Biomarker for Autoimmune/Chronic Inflammatory Diseases?. Frontiers in Immunology, 2013, 4, pp.489. ⟨10.3389/fimmu.2013.00489⟩. ⟨hal-01718196⟩



Record views


Files downloads